SamuelMMoskowitzMD(He/Him)

Pediatric Pulmonology • Newton, MA

Physician

Join to view full profile

Dr. Moskowitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moskowitz's full profile

Already have an account?

Office
28 Manitoba Rd
Newton, MA 02468

Education & Training

University of WashingtonFellowship, Pediatric Pulmonology, 1997 - 2001
University of WashingtonResidency, Pediatrics, 1994 - 1997
Harvard Medical SchoolClass of 1994

Certifications & Licensure

MA State Medical License 2008 - 2025
NH State Medical License 2023 - 2025
AK State Medical License 2006 - 2010
American Board of Pediatrics Pediatric Pulmonology

Clinical Trials

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF) Start of enrollment: 2004 Mar 01
Completed
Not Applicable

Publications & Presentations

PubMed

19 citations
Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.
Isabelle Fajac, Cori Daines, Isabelle Durieu, Jennifer L Goralski, Harry Heijerman
Journal of Cystic Fibrosis. 2023-01-01
43 citations
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous forand a Minimal Function Mutation: A P...
Marcus A Mall, Rossa Brugha, Silvia Gartner, Julian Legg, Alexander Moeller
American Journal of Respiratory and Critical Care Medicine. 2022-12-01
59 citations
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-wee...
Sivagurunathan Sutharsan, Edward F McKone, Damian G Downey, Jamie Duckers, Gordon MacGregor
The Lancet. Respiratory Medicine. 2022-03-01

Press Mentions

Characterization of Pseudomonas Aeruginosa from Subjects with Diffuse PanbronchiolitisOctober 8th, 2024

Grant Support

Polymyxin-Resistant Pseudomonas In CF Lung InfectionNational Institute Of Allergy And Infectious Diseases2009–2010
Polymyxin-Resistant Pseudomonas In CF Lung InfectionNational Institute Of Allergy And Infectious Diseases2007–2008
Standard Versus Biofilm Susceptibility Testing In Cystic Fibrosis (CF)National Center For Research Resources2006
Influence Of ENAC Regulators On CF Lung SeverityNational Heart, Lung, And Blood Institute2005–2006
Genetics Of Cystic Fibrosis Lung SparingNational Center For Research Resources2004–2005
Host-Pathogen Interactions In Cystic FibrosisNational Heart, Lung, And Blood Institute2001–2005
Genetics Of Cystic Fibrosis Lung DiseaseNational Center For Research Resources2004

Industry Relationships

Executive Medical Director, Vertex Pharmaceuticals2015 - 2022